Abzena notes progress with Composite Human Antibody tech
Updated : 15:13
Life sciences group Abzena noted on Friday that Gilead Sciences has announced top line Phase II clinical study results of its product, GS-4997 (selonsertib) in combination with the investigational monoclonal antibody, simtuzumab (SIM) or SIM alone, in patients with non-alcoholic steatohepatitis (NASH).
The AIM-traded firm said simtuzumab is one of twelve products created using Abzena's Composite Human Antibody technology that its partners are progressing in clinical development.
“Gilead has made no statement regarding any other clinical studies of simtuzumab or future development plans for this antibody,” Abzena’s board cautioned.